Idiopathic pulmonary fibrosis: prime time for a precision-based approach to treatment with N-acetylcysteine
- PMID: 33402374
- DOI: 10.1183/13993003.03551-2020
Idiopathic pulmonary fibrosis: prime time for a precision-based approach to treatment with N-acetylcysteine
Conflict of interest statement
Conflict of interest: A.J. Podolanczuk has nothing to disclose. Conflict of interest: I. Noth reports personal fees for consultancy from Boehringer Ingelheim and Genentech HLR, personal fees for consultancy and provision of research materials from Zambon, grants from NIH/NHLBI (UG3HL145266), outside the submitted work; and has a patent on TOLLIP and IPF pending. Conflict of interest: G. Raghu reports consultancy for Zambon and grants from NIH, during the conduct of the study.
Comment on
-
Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial.Eur Respir J. 2021 Jan 5;57(1):2000348. doi: 10.1183/13993003.00348-2020. Print 2021 Jan. Eur Respir J. 2021. PMID: 32703779 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources